Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143.

anitocabtagene autoleucel (CART-ddBCMA) - Gilead, Kite Pharma

FCARH143 - BMS, Fred Hutchinson Cancer Center, National Cancer Institute

Carvykti (ciltacabtagene autoleucel) - J&J

Abecma (idecabtagene vicleucel) - BMS

Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143. (PubMed, Transl Cancer Res) - Sep 12, 2026 - No abstract available
Journal • Hematological Malignancies • Multiple Myeloma • Oncology

http://www.ncbi.nlm.nih.gov/pubmed/42724501

Bryanna Reinhardt; Muhamed Baljevic; Phyu Thin Naing

Sep 12, 2026